title: Relationship of C-reactive protein, metabolic syndrome and diabetes mellitus: potential role of statins.
abstract: Atherosclerosis and the metabolic derangements of insulin resistance, metabolic syndrome and diabetes mellitus are all associated with underlying inflammatory processes. C-reactive protein (CRP), a marker of inflammation, has been shown to be a strong independent predictor of vascular events. It adds to cardiovascular disease risk at all levels of low-density-lipoprotein cholesterol and Framingham risk scores, and elevated levels are also associated with increasing severity of the metabolic syndrome. The development of a simple, stable, noninvasive test to measure high-sensitivity CRP has provided a clinical tool that may have an important role in the identification and assessment of individuals likely to develop cardiovascular or metabolic disease. The role of CRP in predicting cardiovascular risk is less clear in African Americans, however, than in white populations. Statins and thiazolidinediones are being investigated for their potential role in the prevention and treatment of the inflammatory processes involved in the metabolic syndrome and cardiovascular disease. In the future, assessment of CRP levels may contribute importantly to clinical decision-making in reducing cardiovascular risk.
authors.affiliation: Syracuse Preventive Cardiology, State University of New York Health Sciences Center, Syracuse, NY 13202, USA. davidtnash@aol.com
authors.forename: David T
authors.initials: DT
authors.lastname: Nash
mesh_terms: D050197:Atherosclerosis / Q000503:physiopathology* / Q000517:prevention & control; D015415:Biomarkers; D002097:C-Reactive Protein / Q000032:analysis* / Q000187:drug effects; D003920:Diabetes Mellitus / Q000503:physiopathology* / Q000517:prevention & control; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D007249:Inflammation / Q000503:physiopathology; D024821:Metabolic Syndrome / Q000503:physiopathology* / Q000517:prevention & control; D018570:Risk Assessment; D012307:Risk Factors; D045162:Thiazolidinediones / Q000494:pharmacology
chemical_list: D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D045162:Thiazolidinediones; D002097:C-Reactive Protein